Activation of the renal GLP-1R leads to expression of <i>Ren1</i> in the renal vascular tree.
Endocrinol Diabetes Metab · 2021
Last updated 2026-05-28A study in mice found that a single or repeated dose of the GLP-1 drugs liraglutide or semaglutide increased the expression of a gene called *Ren1* in the muscle cells of kidney blood vessels compared to a control group, with statistical significance (p < .0001). This suggests that GLP-1 drugs may affect kidney function by influencing this gene.
AI summary of the abstract below.
| Journal | Endocrinol Diabetes Metab, 2021 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.33 |
| NIH percentile | 20 |
| Molecules | — |
| Conditions studied | Chronic Kidney Disease |
Abstract
The GLP-1 receptor (GLP-1R) in the kidney is expressed exclusively in vascular smooth muscle cells in arteries and arterioles. Downstream effects of the activation of the renal vascular GLP-1R are elusive but may involve regulation of the renin-angiotensin-aldosterone system (RAAS). The expression of in the mouse renal vasculature was investigated by in situ hybridization after a single subcutaneous dose of liraglutide, semaglutide and after repeated injections of liraglutide. Single and repeated exposure to GLP-1R agonists induced expression of in the renal vascular smooth muscle cell compartment compared with vehicle injected controls ( < .0001) for both semaglutide and liraglutide. The present data show a robust induction of expression in the vascular smooth muscle cells of the kidney after single and repeated GLP-1R activation and this renin recruitment may be involved in the effects of GLP-1R agonist treatment on kidney disease.
Verbatim abstract via PubMed 34277961 ↗